Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What has been crazy is the pps drop over the past month or so. This should move back up quickly now. The market cap was/is crazy low. Congrats to those who bought at or near the low.
ESS new out:
SAN FRANCISCO and GENEVA, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced the Company's intention to strategically focus the majority of its resources on the development of Engineered Skin Substitute (ESS) for the treatment of rare pediatric diseases, including the treatment of pediatric severe burns and Congenital Giant Hairy Nevus. Management believes the ESS program represents a vast commercialization opportunity and its near term advancement is critical to the Company's overall business strategy. Additionally, treatments in development for rare pediatric diseases in the United States are eligible to receive Rare Pediatric Disease Designation (RPDD). The Sponsor of a treatment that is approved by the US Food and Drug Administration (FDA) under the RPDD pathway is entitled to receive a Priority Review Voucher (PRV).
"With the integration of the Cutanogen acquisition now complete, we have unearthed powerful human clinical data that validates the significant potential for the ESS program beyond the areas of adult and pediatric severe burns and into Congenital Giant Hairy Nevus," said Gerald E. Commissiong, President & CEO of Amarantus. "It is important for us to now focus the majority of our resources over the next several months on the ESS program. Upon completion of our review of the long-term longitudinal data, we intend to work closely with the FDA in an effort to establish a shortened clinical development pathway to approval via the RPDD pathway."
In the scientific publication Plastic and Reconstructive Surgery. 2004;114(6):1523-1528 entitled "Autologous cultured skin substitutes conserve donor autograft in elective treatment of congenital giant melanocytic nevus," the authors reported on the treatment of two (2) cases of Congenital Giant Hairy Nevus.
You make a statement then follow it with the fact that you don't know if your statement was true. Maybe a wise approach would be to wait and see because the dollar amounts don't support your "almost all" statement.
2 less toxics
Discover Growth out and Dominion significant reduced.
See the glass can be half FULL!!
Indeed. They also closed out a nice portion of debt held by Dominion. Appears to be good news and could reduce the selling pressure.
Interesting:
@JackBrewerBSI: Amazing day at the #BankOfChina! #AMBS #IMUN #BRTX @jbfworldwide… https://t.co/w7alGfuYo8
International interest in ESS? Wouldn't be the first time China was looking to acquire ESS.
I think we are seeing the affects of piecemeal financing on the OTC. Which is why Gerald wants to get on the Nasdaq sooner than later.
Gerald appeared to be feeling the stress of running a publicly traded company at the SHM. I would have to think that pressure is at all time highs.
In a wait and see pattern. Clearly something hasn't played out as planned.
Sick looking chart for sure, enter oversold territory again with the RSI at 27. Should be good for a technical bounce in the next day or two. From what level is anyones guess.
An update is certainly needed...this is tough to watch.
The company is not looking to sell anything on the Therapeutics side! Unless the number is in the hundreds of millions or higher then anything is for sale.
Thank you and I am not really guessing only reiterating the companies stated milestone guidance. I agree that making predictions is a fools game. Should be an interesting week or two ahead.
I think it will be a Thanksgiving spin off. Once the uplist is complete they will focus on CLIA for those two diagnostics. Spinning them off when on the verge of having CLIA certification would be optimal.
I completely agree, there are many options! The sciences continues to improve across all fronts so no need to panic or jump ship now.
Something on the diagnostics side. My guess would be Lympro because MSPrecise has a much higher market opportunity. Both are 4 months or less away from getting CLIA certified so they are both near term revenue generators.
Or they could simply sell off one of the assets then uplist. But I suppose it's much more fun for you to paint the ugliest picture in attempt to further sow the seeds of doubt and fear.
No. I think they are more likely to sell of an asset.
I think near term its a 50/50 shot at this point. People here will through out all kinds of information but the firms representing AMBS didn't file for the uplist if the company didn't meet the requirments. To me it depends on how far along the company was in the uplisting process prior to the quorum issue.
I don't think most of those posting on this subject are looking to misrepresent the facts but trying to explain the consistent selling pressure the stock has been under. I have not went back to read the latest filings.
One thing is a given. There is a buy for every sell. Some big buyers in the $2 range.
Let me start by saying I haven't had time to go back and review the filing but if what redspeed posted about the 180 days is correct then AMBS could have issued the shares to Diogenix back in July when the PPS was in the $6 range. If that occurred then it wouldn't be the 8 times as many share from the current PPS it would only be 2 times(roughly) the shares from the PPS back in July. I guess we will only know for sure once the 3rd quarter filings are out.
Very nice, 2nd ODD for MANF will get some attention from BP.
SAN FRANCISCO and GENEVA, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that the U.S. Food and Drug Administration (FDA) has granted the company's investigational drug mesencephalic-astrocyte-derived neurotrophic factor (MANF) orphan drug designation for the treatment of retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
MANF, a naturally-occurring protein that reduces and prevents apoptosis (programmed cell death) in response to injury or disease, was discovered utilizing Amarantus' proprietary PhenoGuard™ Protein Discovery Engine. Pre-clinical data demonstrated that MANF provided protective functional effects in an animal model of RAO. Moreover, toxicology studies have demonstrated that MANF was well-tolerated following a single intravitreal administration of a therapeutically relevant dose.
"We are extremely pleased to have received the second orphan drug designation for MANF for use in ophthalmologic disorders. At the end of 2014 we received orphan drug designation for MANF to treat retinitis pigmentosa (RP), and this additional designation for treatment of RAO is an important step in our regulatory strategy for what we believe has the potential to become a broad ophthalmic therapeutic franchise," said Gerald E. Commissiong, President & CEO of Amarantus BioSciences Holdings, Inc. "RAO is an acute condition that can potentially lead to blindness and the toxicology data generated thus far directly supports the translational potential for MANF in this indication. We believe MANF has promise as a safe and effective therapeutic option to treat RAO and RP."
The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.
Is it a joke now? AMBS long
Best of luck getting in at the right time. The Nasdaq listing news will likely give the share price a nice boost. I think there are many who are waiting on news to get in.
So why would you care if what I posted was good or bad news? Should matter none to you.
Correct, so he probably has left the company. I know I would look elsewhere for work when the company I work for is selling the division I am running. Sounds like to be he choose to leave before becoming unemployed.
I didn't express the news as good or bad, however I don't see it as bad. And for the record it's a "she" and anyone following the company would know that.
Good to see AMBS networking with some big names abroad the past couple days.
http://www.neurotechconfeurope.com
Next week Amarantus will host the first ever MANF Symposium.
Seems like a real good time to announce the NASDAQ uplist.
I confirmed with the company IR person that AMBS is still working with NASDAQ on the uplist.
You all leave out the fact that ESS has been used to save lives on people walking around today! Yes there were mistakes in trails but from what I have read it was documentation errors. The effectiveness of ESS is not at all in question among the experts in the field of severe burns. It is also a fact the AMBS does have $750k of DoD funding from the old grant.
Great post redspeed. The market cap has dipped insanely low at under $17 million. Once on the Nasdaq and institutions begin buying the true value of the pipeline will be reflected in the PPS. The analyst targets of the PPS in the mid teens are well within reach late this year or early next with the company hitting projected milestones.
Amarantus needs the Nasdaq uplisting to happen sooner than later. There are several key milestones to be reached over the next 4 months that will attract big institutional interest, IMO.
-CLIA for LymPro and MSPrecise
-ESS updates from the Army Institute/Rutgers collaboration
-Second ODD for MANF (for RAO)
These will mean something to institutions and lead them to buy in(through the Shelf Offering) for the long term giving AMBS the financing needed to advance the pipeline.
Right now past financing deals are kicking the PPS into the dirt.
Not sure, probably just sits there.
Previous Stock Value: Par Value Shares: 13,333,334 Value: $ 0.001 Par Value Shares: 10,000,000 Value: $ 0.001 No Par Value Shares: 0 ----------------------------------------------------------------- Total Authorized Capital: $ 23,333.33 New Stock Value: Par Value Shares: 35,000,000 Value: $ 0.001 Par Value Shares: 10,000,000 Value: $ 0.001 No Par Value Shares: 0 ----------------------------------------------------------------- Total Authorized Capital: $ 45,000.00
Shorty getting nervous maybe...got 5 posts this morning instead of the usual 3 or 4....stepping up his game. AMBS
How can that be? I see volume on the chart from that time period... Are you saying there wasn't a buy for every sell? I must be confused on how the stock market works maybe you can explain.
Your timeframe is a bit off, they have until January 13, 2016 to exercise the Georgetown option. Even if they don't it's only $75,000 to extend the option agreement.
However once the Shelf Offering comes into play the option will be exercised. My crystal balls says November...
May not want to get caught short here....
Didn't take much buying to move this up 18%.....
Imagine when Nasdaq news hits...shorty will feel da squeeze...
Looking solid right now. Won't take much for this to continue on up.
Indeed. Nice to see some buying, let's see if it continues.
GC has already stated the company is NOT looking at any further asset purchases...i believe he realizes that he has his hand full with the current boat load.
Nasdaq listing will happen, IMO.
time for Nasdaq uplisting news!